3/12
01:03 pm
mbx
MBX Biosciences (MBX) had its "buy" rating reaffirmed by TD Cowen.
Medium
Report
MBX Biosciences (MBX) had its "buy" rating reaffirmed by TD Cowen.
3/12
08:38 am
mbx
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Medium
Report
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/12
08:00 am
mbx
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Low
Report
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
3/10
08:32 am
mbx
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer [Yahoo! Finance]
Medium
Report
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer [Yahoo! Finance]
3/10
08:00 am
mbx
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Medium
Report
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
3/9
12:06 pm
mbx
MBX Biosciences (MBX) was given a new $50.00 price target by Truist Financial Corporation.
Medium
Report
MBX Biosciences (MBX) was given a new $50.00 price target by Truist Financial Corporation.
3/9
10:21 am
mbx
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Medium
Report
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
3/9
08:02 am
mbx
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism [Yahoo! Finance]
Medium
Report
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism [Yahoo! Finance]
3/9
08:00 am
mbx
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Medium
Report
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
3/7
07:03 pm
mbx
MBX Biosciences CFO Shift Puts Funding And Execution In Focus [Yahoo! Finance]
Medium
Report
MBX Biosciences CFO Shift Puts Funding And Execution In Focus [Yahoo! Finance]
2/28
07:16 pm
mbx
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway [Yahoo! Finance]
Low
Report
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway [Yahoo! Finance]
2/24
12:05 pm
mbx
MBX Biosciences (NASDAQ:MBX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
MBX Biosciences (NASDAQ:MBX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
2/23
08:13 am
mbx
MBX Biosciences to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Medium
Report
MBX Biosciences to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/23
08:00 am
mbx
MBX Biosciences to Participate in Upcoming March Investor Conferences
Medium
Report
MBX Biosciences to Participate in Upcoming March Investor Conferences
2/11
08:53 am
mbx
MBX Biosciences to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
MBX Biosciences to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/11
08:00 am
mbx
MBX Biosciences to Participate in Upcoming Investor Conferences
Medium
Report
MBX Biosciences to Participate in Upcoming Investor Conferences
1/29
07:41 am
mbx
MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
mbx
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/23
07:09 pm
mbx
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return [Yahoo! Finance]
Medium
Report
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return [Yahoo! Finance]
1/22
08:00 am
mbx
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
Low
Report
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
1/11
07:40 pm
mbx
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
High
Report
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
04:00 pm
mbx
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
High
Report
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/9
06:10 am
mbx
MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
02:01 am
mbx
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
High
Report
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
12/21
01:08 am
mbx
High
Report